Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX-EGF (panitumumab) in advanced NSCLC
NCT00101920Phase 2Completed
- Sponsor
- Amgen
- Start
- Jun 2003
- Primary completion
- Dec 2004
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of panitumumab in non-small cell lung cancer (NSCLC), sponsored by Amgen. Started Jun 2003; status: completed.
02
Drugs
panitumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00101920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00101920.